Previous close | 1.0300 |
Open | 1.0300 |
Bid | 0.3500 |
Ask | 2.4000 |
Strike | 290.00 |
Expiry date | 2024-01-19 |
Day's range | 1.0300 - 1.0300 |
Contract range | N/A |
Volume | |
Open interest | 174 |
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market.
Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech.